AstraZeneca delivers 5.3 million doses of COVID-19 vaccine to Thailand in August

AstraZeneca confirmed today that it delivered an additional 5.3 million doses of COVID-19 Vaccine AstraZeneca to the Ministry of Public Health in August. A total of 16.6 million doses of AstraZeneca’s vaccine have now been delivered to Thailand, as part of an aim to deliver 61 million before the end of this year.

The August deliveries to Thailand meet AstraZeneca’s projections for the month, which had forecast between five and six million doses.

James Teague, Country President, AstraZeneca (Thailand) Ltd., said: “There continues to be no higher priority for AstraZeneca in Thailand than manufacturing vaccines that can protect everyone as fast as possible. In partnership with Siam Bioscience, we continue operate at full manufacturing capacity and are leaving no stone unturned to increase supply further still.”

Since the first international launches in early 2021, the vaccine has helped prevent hundreds of thousands of hospitalisations and helped save tens of thousands of lives.1

COVID-19 Vaccine AstraZeneca is 80-90% effective against severe disease and hospitalisation and is effective against all severities of COVID-19 across all adult age groups.2,3 The vaccine is effective against WHO-identified variants of concern including the current circulating Beta and Delta variants.2,3  

COVID-19 Vaccine AstraZeneca has been shown to be generally well tolerated. Incidents of thrombosis with thrombocytopenia (TTS), an extremely rare blood disorder, have been reported in a small number of people who received the vaccine within 14 days of the first dose which reduced to rates expected in the general population after the second dose.4

To date, AstraZeneca and its partners have released for supply more than one billion doses of vaccine to over 170 countries; approximately two-thirds of these have been delivered to low- and lower-middle income countries.

COVID-19 Vaccine AstraZeneca

The COVID-19 Vaccine AstraZeneca, (ChAdOx1-S [Recombinant]), formerly AZD1222, was co-invented by the University of Oxford and its spin-out company, Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contact

For further details please contact Pucharapan Holim, Communications Manager, pucharapan.holim@astrazeneca.com, +66 (0) 86 999 8587.

References

1. AZD1222 lives and hospitalisations saved data on file. Data on File Number: REF-117162 June 23, 2021. AstraZeneca UK Ltd.

2. AstraZeneca PLC.COVID-19 Vaccine AstraZeneca confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials. [Online]. Available at: https://www.astrazeneca.com/media-centre/press-releases/2021/covid-19-vaccine-astrazeneca-confirms-protection-against-severe-disease-hospitalisation-and-death-in-the-primary-analysis-of-phase-iii-trials.html [Accessed: 21 Mar 2021].

3. Public Health England COVID-19 vaccine surveillance report Week 20. Available at COVID-19 vaccine surveillance report - week 20 (publishing.service.gov.uk) [Accessed: July 2021].

4. P. Bhuyan et al. Thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis of rare cases. Lancet. Available at: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01693-7/fulltext. Accessed July 2021.